Literature DB >> 24815305

Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay.

Eric T Lofgren1, Stephen R Cole, David J Weber, Deverick J Anderson, Rebekah W Moehring.   

Abstract

BACKGROUND: Clostridium difficile is a health care-associated infection of increasing importance. The purpose of this study was to estimate the time until death from any cause and time until release among patients with C. difficile, comparing the burden of those in the intensive care unit (ICU) with those in the general hospital population.
METHODS: A parametric mixture model was used to estimate event times, as well as the case-fatality ratio in ICU and non-ICU patients within a cohort of 609 adult incident cases of C. difficile in the Southeastern United States between 1 July 2009 and 31 December 2010.
RESULTS: ICU patients had twice the median time to death (relative time = 1.97 [95% confidence interval (CI) = 0.96-4.01]) and nearly twice the median time to release (1.88 [1.40-2.51]) compared with non-ICU patients. ICU patients also experienced 3.4 times the odds of mortality (95% CI = 1.8-6.2). Cause-specific competing risks analysis underestimated the relative survival time until death (0.65 [0.36-1.17]) compared with the mixture model.
CONCLUSIONS: Patients with C. difficile in the ICU experienced higher mortality and longer lengths of stay within the hospital. ICU patients with C. difficile infection represent a population in need of particular attention, both to prevent adverse patient outcomes and to minimize transmission of C. difficile to other hospitalized patients.

Entities:  

Mesh:

Year:  2014        PMID: 24815305      PMCID: PMC4224274          DOI: 10.1097/EDE.0000000000000119

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  13 in total

1.  Inference for mutually exclusive competing events through a mixture of generalized gamma distributions.

Authors:  William Checkley; Roy G Brower; Alvaro Muñoz
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

2.  Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies.

Authors:  Stephen R Cole; Rui Li; Kathryn Anastos; Roger Detels; Mary Young; Joan S Chmiel; Alvaro Muñoz
Journal:  Stat Med       Date:  2004-11-15       Impact factor: 2.373

3.  The network approach for prevention of healthcare-associated infections: long-term effect of participation in the Duke Infection Control Outreach Network.

Authors:  Deverick J Anderson; Becky A Miller; Luke F Chen; Linda H Adcock; Evelyn Cook; A Lynn Cromer; Susan Louis; Paul A Thacker; Daniel J Sexton
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

4.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

Review 5.  Economic healthcare costs of Clostridium difficile infection: a systematic review.

Authors:  S S Ghantoji; K Sail; D R Lairson; H L DuPont; K W Garey
Journal:  J Hosp Infect       Date:  2010-02-12       Impact factor: 3.926

6.  Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

7.  Methods for estimating the case fatality ratio for a novel, emerging infectious disease.

Authors:  A C Ghani; C A Donnelly; D R Cox; J T Griffin; C Fraser; T H Lam; L M Ho; W S Chan; R M Anderson; A J Hedley; G M Leung
Journal:  Am J Epidemiol       Date:  2005-08-02       Impact factor: 4.897

8.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

9.  Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection.

Authors:  Ajay K Sethi; Wafa N Al-Nassir; Michelle M Nerandzic; Greg S Bobulsky; Curtis J Donskey
Journal:  Infect Control Hosp Epidemiol       Date:  2010-01       Impact factor: 3.254

10.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

View more
  21 in total

Review 1.  ICU director data: using data to assess value, inform local change, and relate to the external world.

Authors:  David J Murphy; Ogbonna C Ogbu; Craig M Coopersmith
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

Review 2.  Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention.

Authors:  Irene K Louh; William G Greendyke; Emilia A Hermann; Karina W Davidson; Louise Falzon; David K Vawdrey; Jonathan A Shaffer; David P Calfee; E Yoko Furuya; Henry H Ting
Journal:  Infect Control Hosp Epidemiol       Date:  2017-04       Impact factor: 3.254

3.  External Validation and Comparison of Clostridioides difficile Severity Scoring Systems.

Authors:  D Alexander Perry; Daniel Shirley; Dejan Micic; Pratish C Patel; Rosemary Putler; Anitha Menon; Vincent B Young; Krishna Rao
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

4.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

5.  Thrombocytopenia in hospitalized patients with severe clostridium difficile infection.

Authors:  Eric M Fountain; Maggie C Moses; Lawrence P Park; Christopher W Woods; Gowthami M Arepally
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 6.  Novel approaches to treating Clostridium difficile-associated colitis.

Authors:  David Padua; Charalabos Pothoulakis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-07       Impact factor: 3.869

7.  Estimating Local Costs Associated With Clostridium difficile Infection Using Machine Learning and Electronic Medical Records.

Authors:  Theodore R Pak; Kieran I Chacko; Timothy O'Donnell; Shirish S Huprikar; Harm van Bakel; Andrew Kasarskis; Erick R Scott
Journal:  Infect Control Hosp Epidemiol       Date:  2017-11-06       Impact factor: 3.254

8.  Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells.

Authors:  Stefano Gigli; Luisa Seguella; Marcella Pesce; Eugenia Bruzzese; Alessandra D'Alessandro; Rosario Cuomo; Luca Steardo; Giovanni Sarnelli; Giuseppe Esposito
Journal:  United European Gastroenterol J       Date:  2017-03-13       Impact factor: 4.623

9.  Predictors of Mortality Among a National Cohort of Veterans With Recurrent Clostridium difficile Infection.

Authors:  Haley J Appaneal; Aisling R Caffrey; Maya Beganovic; Sanja Avramovic; Kerry L LaPlante
Journal:  Open Forum Infect Dis       Date:  2018-07-19       Impact factor: 3.835

10.  Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.

Authors:  F Eun-Hyung Lee; John L Daiss; Natalie S Haddad; Sophia Nozick; Geena Kim; Shant Ohanian; Colleen S Kraft; Paulina A Rebolledo; Yun Wang; Hao Wu; Adam Bressler; Sang Nguyet Thi Le; Merin Kuruvilla; Martin C Runnstrom; Richard P Ramonell; L Edward Cannon
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 11.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.